Onkológia 1/2022

Pitfalls of diagnosis and treatment of primary urothelial prostate cancer during the COVID-19 pandemic

Introduction: Diagnosis and treatment of primary urothelial prostate cancer is different from that of classic prostate adenocarcinoma. Transient cell prostate cancer was first described in 1952 by Mellicow and Hollowel. It shows highly biological aggressive and has a poor prognosis. The origin in the prostatic part of the urethra is referred to as the primary type. Case: The aim of this paper is a case report in which we present the pitfalls of diagnosing prostate cancer (KP) from the transient epithelium in a 65-year-old patient, while the diagnosis and treatment was complicated by circumstances associated with the COVID-19 pandemic. Conclusion: Diagnosis of urothelial prostate cancer is difficult even under standard conditions. A multidisciplinary approach is important in the treatment of the disease. The combination of radical surgical and oncological adjuvant treatment is currently the method of choice.

Keywords: prostatitis, hematuria, MRI, biopsy, primary urothelial prostate cancer, chemotherapy